Beneficial effects of combined AT1 receptor/neprilysin inhibition (ARNI) versus AT1 receptor blockade alone in the diabetic eye

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 15, 2016, Pages 6722-6730

  Prasad, Tuhina ^a   Roksnoer, Lodi C W ^b   Zhu, Ping ^a   Verma, Amrisha ^a   Li, Yiming ^a   Batenburg, Wendy W ^b   de Vries, René ^b   Jan Danser, A H ^b   Li, Qiuhong ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angiotensin receptor blocker; AT1 receptor; Diabetes; Diabetic retinopathy; Irbesartan; Neprilysin; Renin angiotensin system; Thiorphan

Indexed keywords

CELL MARKER; IRBESARTAN; PENTOBARBITAL; STREPTOZOCIN; THIORPHAN; TRYPSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; GLIAL FIBRILLARY ACID PROTEIN, RAT; GLIAL FIBRILLARY ACIDIC PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; RNA; TETRAZOLE DERIVATIVE;

ADULT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL DEATH; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC RETINOPATHY; GLIOSIS; GLUCOSE BLOOD LEVEL; IMMUNOFLUORESCENCE TEST; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; VASCULARIZATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; METABOLISM; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT; TRANSGENIC RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; NEPRILYSIN; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; RNA; TETRAZOLES; THIORPHAN;

EID: 85006412333     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.16-20289     Document Type: Article

References (49)

1. Wong TY, Cheung CM, Larsen M, Sharma S, Simo R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012.
2. Estacio RO, McFarling E, Biggerstaff S, Jeffers BW, Johnson D, Schrier RW. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM. Am J Kidney Dis. 1998;31:947-953.
3. Giacchetti G, Sechi LA, Rilli S, Carey RM. The reninangiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocr Metab. 2005;16:120-126.
4. Cohn JN. Role of the renin-angiotensin system in cardiovascular disease. Cardiovasc Drugs Ther. 2010;24:341-344.
5. Ghattas A, Lip PL, Lip GY. Renin-angiotensin blockade in diabetic retinopathy. Int J Clin Pract. 2011;65:113-116.
6. Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res. 2010;29:284-311.
7. Hanes DS, Nahar A, Weir MR. The tissue renin-angiotensinaldosterone system in diabetes mellitus. Curr Hyperten Rep. 2004;6:98-105.
8. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40-51.
9. Seymour AA, Norman JA, Asaad MM, et al. Antihypertensive and renal activity of SQ 28,603, an inhibitor of neutral endopeptidase. J Cardiovasc Pharmacol. 1991;17:296-304.
10. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255-1266.
11. McMurray JJ, O’Connor C. Lessons from the TOPCAT trial. New Engl J Med. 2014;370:1453-1454.
12. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. New Engl J Med. 2014;371:993-1004.
13. McMurray JJ, Packer M, Solomon SD. Neprilysin inhibition for heart failure. New Engl J Med. 2014;371:2336-2337.
14. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380:2129-2143.
15. Salomon JA, Wang H, Freeman MK, et al. Healthy life expectancy for 187 countries, 1990-2010: a systematic analysis for the Global Burden Disease Study 2010. Lancet. 2012;380:2144-2162.
16. Roksnoer LCW, van Veghel R, Clahsen-van Groningen MC, et al. Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition versus AT1 receptor blockade alone. Clin Sci (Lond). 2016;130: 1209-1220.
17. Batenburg WW, Verma A, Wang Y, et al. Combined renin inhibition/(pro)renin receptor blockade in diabetic retinopathy-a study in transgenic (mREN2)27 rats. PLoS One. 2014;9: e100954.
18. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int. 1998;54:343-352.
19. Moravski CJ, Skinner SL, Stubbs AJ, et al. The reninangiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol. 2003;162:151-160.
20. Wilkinson-Berka JL, Tan G, Binger KJ, et al. Aliskiren reduces vascular pathology in diabetic retinopathy and oxygeninduced retinopathy in the transgenic (mRen-2)27 rat. Diabetologia. 2011;54:2724-2735.
21. Roksnoer LCW, van Veghel R, de Vries R, et al. Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats. Kidney Int. 2015;88:109-120.
22. Johnson MS, DeMarco VG, Heesch CM, et al. Sex differences in baroreflex sensitivity, heart rate variability, and end organ damage in the TGR(mRen2)27 rat. Am J Physiol Heart Circ Physiol. 2011;301:H1540-1550.
23. van Esch JHM, Moltzer E, van Veghel R, et al. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens. 2010;28:21-2155.
24. Katsuda T, Tsuchiya R, Kosaka N, et al. Human adipose tissuederived mesenchymal stem cells secrete functional neprilysinbound exosomes. Sci Rep. 2013;3:1197.
25. Miners JS, Verbeek MM, Rikkert MO, Kehoe PG, Love S. Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J Neurosci Methods. 2008;167:229-236.
26. Li Q, Verma A, Han PY, et al. Diabetic eNOS-knockout mice develop accelerated retinopathy. Invest Ophthalmol Vis Sci. 2010;51:5240-5246.
27. Belluardo P, Cataliotti A, Bonaiuto L, et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006;291:H1529-H1535.
28. Macheret F, Heublein D, Costello-Boerrigter LC, et al. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol. 2012;60:1558-1565.
29. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594-600.
30. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357-2368.
31. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013;34:886-893c.
32. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27:47-72.
33. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;341-366.
34. Cammarata PR, Braun B, Dimitrijevich SD, Pack J. Characterization and functional expression of the natriuretic peptide system in human lens epithelial cells. Mol Vis. 2010;16:630-638.
35. Dahrouj M, Alsarraf O, Liu Y, Crosson CE, Ablonczy Z. C-type natriuretic peptide protects the retinal pigment epithelium against advanced glycation end product-induced barrier dysfunction. J Pharmacol Exp Ther. 2013;344:96-102.
36. Hara H, Oh-hashi K, Yoneda S, et al. Elevated neprilysin activity in vitreous of patients with proliferative diabetic retinopathy. Mol Vis. 2006;12:977-982.
37. Lara-Castillo N, Zandi S, Nakao S, et al. Atrial natriuretic peptide reduces vascular leakage and choroidal neovascularization. Am J Pathol. 2009;175:2343-2350.
38. Xing J, Moldobaeva N, Birukova AA. Atrial natriuretic peptide protects against Staphylococcus aureus-induced lung injury and endothelial barrier dysfunction. J Appl Physiol. 2011;110: 213-224.
39. Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet. 1998;351:1657-1658.
40. Martin FL, Stevens TL, Cataliotti A, et al. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int. 2005;67: 1723-1730.
41. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2:663-670.
42. Tummala R, Bhadra R, Gupta A, Ghosh RK. Combined neprilysin and RAS inhibition in cardiovascular diseases: a review of clinical studies. J Cardiovasc Pharmacol. 2016;68: 183-190.
43. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hyperten. 2004;17:103-111.
44. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608-609.
45. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387-1395.
46. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Ab by neprilysin. Science. 2001;292:1550-1552.
47. Ding JD, Johnson LV, Herrmann R, et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108:E279-E287.
48. Ning A, Cui J, To E, Ashe KH, Matsubara J. Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci. 2008;49:5136-5143.
49. Yoshida T, Ohno-Matsui K, Ichinose S, et al. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest. 2005;115:2793-2800.